Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 83

1.

Serum antibodies against CD28-- a new potential marker of dismal prognosis in melanoma patients.

Körner R, Preuss KD, Fadle N, Madjidi D, Neumann F, Bergeler L, Gräber S, Müller CS, Grünhage F, Pfreundschuh M, Lammert F, Vogt T, Pföhler C.

PLoS One. 2013;8(3):e58087. doi: 10.1371/journal.pone.0058087. Epub 2013 Mar 6.

2.

Autoimmune antibodies and recurrence-free interval in melanoma patients treated with adjuvant interferon.

Bouwhuis MG, Suciu S, Collette S, Aamdal S, Kruit WH, Bastholt L, Stierner U, Salès F, Patel P, Punt CJ, Hernberg M, Spatz A, ten Hagen TL, Hansson J, Eggermont AM; EORTC Melanoma Group and the Nordic Melanoma Group.

J Natl Cancer Inst. 2009 Jun 16;101(12):869-77. doi: 10.1093/jnci/djp132. Epub 2009 Jun 9.

PMID:
19509353
3.

Increased number of cytotoxic CD3+ CD28- gammadelta T cells in peripheral blood of patients with cutaneous malignant melanoma.

Campillo JA, Martínez-Escribano JA, Minguela A, López-Alvarez R, Marín LA, García-Alonso AM, Bensussan A, Alvarez-López MR.

Dermatology. 2007;214(4):283-8.

PMID:
17460398
4.
5.

Autoantibodies against CD28 are associated with atopic diseases.

Neuber K, Mähnss B, Hübner C, Gergely H, Weichenthal M.

Clin Exp Immunol. 2006 Nov;146(2):262-9.

6.

Significance of plasma cytokine levels in melanoma patients with histologically negative sentinel lymph nodes.

Porter GA, Abdalla J, Lu M, Smith S, Montgomery D, Grimm E, Ross MI, Mansfield PF, Gershenwald JE, Lee JE.

Ann Surg Oncol. 2001 Mar;8(2):116-22.

PMID:
11258775
7.

Prognostic significance of the sequential detection of circulating melanoma cells by RT-PCR in high-risk melanoma patients receiving adjuvant interferon.

Gogas H, Kefala G, Bafaloukos D, Frangia K, Polyzos A, Pectasides D, Tsoutsos D, Panagiotou P, Ioannovich J, Loukopoulos D.

Br J Cancer. 2002 Jul 15;87(2):181-6.

8.

Serum values of tumour necrosis factor-alpha and of soluble tumour necrosis factor-R55 in melanoma patients.

Ocvirk J, Stabuc B, Rudolf Z, Galvani V, Curin-Serbec V.

Melanoma Res. 2000 Jun;10(3):253-8.

PMID:
10890379
9.

Prognostic value of serum p53 antibodies in patients with resected non-small cell lung cancer.

Laudanski J, Burzykowski T, Niklinska W, Chyczewski K, Furman M, Niklinski J.

Lung Cancer. 1998 Dec;22(3):191-200.

PMID:
10048472
10.

Cathepsins B, H, and L and their inhibitors stefin A and cystatin C in sera of melanoma patients.

Kos J, Stabuc B, Schweiger A, Krasovec M, Cimerman N, Kopitar-Jerala N, Vrhovec I.

Clin Cancer Res. 1997 Oct;3(10):1815-22.

11.

SOX2 autoantibodies as noninvasive serum biomarker for breast carcinoma.

Sun Y, Zhang R, Wang M, Zhang Y, Qi J, Li J.

Cancer Epidemiol Biomarkers Prev. 2012 Nov;21(11):2043-7. doi: 10.1158/1055-9965.EPI-12-0498. Epub 2012 Jul 25.

12.

Malignant melanoma of the head and neck. Clinical and immunological considerations.

Merimsky O, Fishman P, Feldman I, Shafir R, Rapaport Y, Sheonfeld Y, Chaitchik S.

Am J Clin Oncol. 1996 Aug;19(4):363-7.

PMID:
8677905
13.

Detection of circulating tumor lysate-reactive CD4+ T cells in melanoma patients.

Ladekarl M, Agger R, Fleischer CC, Hokland M, Hulgaard EF, Kirkin A, von der Maase H, Petersen MS, Rytter C, Zeuthen J, Gundersen HJ.

Cancer Immunol Immunother. 2004 Jun;53(6):560-6. Epub 2004 Feb 25.

PMID:
14985861
14.

Prognostic significance of three hepatitis markers (p53 antibodies, vascular endothelial growth factors and alpha fetoprotein) in patients with hepatocellular carcinoma.

Gadelhak NA, Gadelhak SA, El-Morsi DA, Abdelaziz MM, Abbas AT, El-Emshaty HM.

Hepatogastroenterology. 2009 Sep-Oct;56(94-95):1417-24.

PMID:
19950803
15.

Serum anti-p53 autoantibodies in pleural malignant mesothelioma, lung cancer and non-neoplastic lung diseases.

Neri M, Betta P, Marroni P, Filiberti R, Cafferata M, Mereu C, Ivaldi G, Montanaro F, Puntoni R, Paganuzzi M.

Lung Cancer. 2003 Feb;39(2):165-72.

PMID:
12581569
16.

Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome.

Mouawad R, Spano JP, Comperat E, Capron F, Khayat D.

Eur J Cancer. 2009 May;45(8):1407-14. doi: 10.1016/j.ejca.2008.12.015. Epub 2009 Jan 20.

PMID:
19157860
17.

Decreased serum tryptophan concentration predicts poor prognosis in malignant melanoma patients.

Weinlich G, Murr C, Richardsen L, Winkler C, Fuchs D.

Dermatology. 2007;214(1):8-14.

PMID:
17191041
18.

S100B protein, 5-S-cysteinyldopa and 6-hydroxy-5-methoxyindole-2-carboxylic acid as biochemical markers for survival prognosis in patients with malignant melanoma.

Kärnell R, von Schoultz E, Hansson LO, Nilsson B, Arstrand K, Kågedal B.

Melanoma Res. 1997 Oct;7(5):393-9.

PMID:
9429222
19.

[Autoimmunity induced by low doses of interferon in melanoma stage I].

Ballanger F, Allix ML, Rimbert M, Audrain M, Muller JY, Dreno B.

Ann Dermatol Venereol. 2006 Jun-Jul;133(6-7):543-8. French.

PMID:
16885841
20.

Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.

Sugaya M, Miyagaki T, Ohmatsu H, Suga H, Kai H, Kamata M, Fujita H, Asano Y, Tada Y, Kadono T, Okochi H, Sato S.

J Dermatol Sci. 2012 Oct;68(1):45-51. doi: 10.1016/j.jdermsci.2012.07.007. Epub 2012 Jul 27.

PMID:
22884782

Supplemental Content

Support Center